Combination immunotherapy for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests two immunotherapy drugs for people with advanced bile duct or gallbladder cancer that has EGFR protein and has not responded to earlier treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or spread bile duct or gallbladder cancer confirmed by biopsy.
- Your cancer has tested positive for a protein called EGFR (at least 1+ on a scale).
- You have had at least one previous cancer treatment that didn't work.
- You are able to do light activity or are fully active (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Hear when a new Cancer of Biliary Duct trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.